[ad_1]
The company is currently in the final phase of clinical trials for its vaccine candidate in Brazil, Turkey and Indonesia, and is pioneering vaccine production efforts in China. China has at least 5 candidate COVID-19 vaccine candidates for end-stage clinical trials in more than 12 countries.
The pharmaceutical company “Sino Biopharm” bought a 15 percent stake in Senovac, for an investment of 500 million dollars.
Senovac CEO Yin Weidong said in a statement that the funds will enable the company to improve its vaccine sales capabilities, expand into Asian markets, develop and access new technologies, and accelerate our efforts to fight the global pandemic.
Yesterday, 1.2 million doses of the company’s experimental vaccine arrived in Indonesia, where their use is expected to be approved soon.
The Sinovac vaccine is a two-dose inactivated vaccine, which is an old technique by which a live virus is killed and then eliminated.
This vaccine can be stored at 2 to 8 degrees Celsius, within the normal range of the refrigerator, unlike some other vaccines which require much lower temperatures.
The investigational Sinovac vaccine has now been approved for use in emergency situations in China, although it has yet to receive final approval to be placed on the market.
In case of emergency use, it has been distributed to groups deemed appropriate by the Chinese government, including frontline medical workers and border workers.
The company’s latest public data, published in the scientific journal “The Lancet”, showed that the candidate vaccine produced lower levels of antibodies in humans, compared to those who recovered from Covid-19.
[ad_2]
Source link
